COMMUNIQUÉS West-GlobeNewswire

ApolloMD Surpasses $1.5 Billion in Patient Debt Relief Through Ongoing Partnership with Cascade365, Coordinated by Undue Medical Debt
04/05/2026
ATLANTA, May 04, 2026 (GLOBE NEWSWIRE) -- ApolloMD has helped eliminate more than $1.5 billion in patient medical debt since 2018, marking a significant milestone in its ongoing partnership with Cascade365 and its [...]
Flyte Increases Capacity and Launches Hiring Initiative as Spirit Airlines Shutdown Disrupts U.S. Air Travel
04/05/2026
Premium Short-Haul Operator Continues Planned Vision Jet Fleet Expansion and Opens Hiring Pipeline for Impacted Pilots and Aviation Professionals FORT MILL, SC, May 04, 2026 (GLOBE NEWSWIRE) -- — Flyte, the regional air [...]
TimelyCare Acquires Alongside to Expand Continuous Student Support with Clinician-Powered AI Coaching
04/05/2026
Acquisition adds an early-intervention and engagement layer to TimelyCare’s education-first care continuum while preserving continuity for existing partners. Fort Worth, TX, May 04, 2026 (GLOBE NEWSWIRE) -- May 4, 2026 [...]
Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation (corrected time)
04/05/2026
Oslo, Norway, 4 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation of [...]
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
04/05/2026
Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S. Phase 2 single-arm [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/05/2026
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
04/05/2026
PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced [...]
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
04/05/2026
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million ROCKVILLE, MD, May 04, 2026 ( [...]
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
04/05/2026
COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and [...]
Artios Further Expands Leadership Team to Advance Oncology Pipeline and Accelerate Regulatory Execution
04/05/2026
Jeremy B. Fitch, MBA, appointed as Chief Business Officer Michael A. Alrutz, J.D., Ph.D., appointed as General Counsel Guy C. Ruble, PharmD, appointed as VP, Regulatory Affairs CAMBRIDGE, United Kingdom and NEW YORK, [...]
CPTx to present preclinical proof-of-principle of its DNA-based in vivo CAR T platform at ASGCT Annual Meeting
04/05/2026
Oral presentation includes early readouts from preclinical testing of CAR-encoding episomal DNA delivered by targeted lipid nanoparticles CPTx will present two posters at ASGCT 2026 Munich, Germany — May 4, 2026 — CPTx [...]
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
04/05/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies [...]
Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial
04/05/2026
MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs placebo Improvements observed across key symptoms, including nausea, early satiety, [...]
Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial
04/05/2026
MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs placebo Improvements observed across key symptoms, including nausea, early satiety, [...]
Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million
04/05/2026
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to [...]
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
04/05/2026
-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pediatric patients with [...]
4DMT to Participate in Upcoming Investor Conferences
04/05/2026
EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
04/05/2026
Ms. Dac brings more than 30 years of experience successfully executing product launches and scaling commercial organizations for a range of therapeutic areas EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna [...]
Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1
04/05/2026
Data presented at IWGGD 2026 Symposium show a meaningful reduction in bone marrow burden with improvements in bone density LONDON, May 04, 2026 (GLOBE NEWSWIRE) -- Spur Therapeutics today released new data from the [...]

Pages